A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)

Abstract Background Gefitinib (G) is a recommended molecular‐targeted agent for elderly patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). Docetaxel (Doc) and pemetrexed (Pem) have similar efficacies, and either is often used as the sole agent during tre...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Kazuhiro Asami, Masahiko Ando, Takashi Nishimura, Takashi Yokoi, Atsuhisa Tamura, Koichi Minato, Masahide Mori, Fumitaka Ogushi, Akiyoshi Yamamoto, Hiroshige Yoshioka, Masaaki Kawahara, Shinji Atagi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2022-06-01
Serie:	Thoracic Cancer
Soggetti:	chemotherapy elderly epidermal growth factor receptor mutation gefitinib non‐small cell lung cancer
Accesso online:	https://doi.org/10.1111/1759-7714.14465
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!